Skip links

Multi-Cancer

Early Detection Test

Detect a range of cancer through a simple blood test. It aims to catch early-stage cancer cells long before symptoms appear.

Examine

Examine over 100,000 DNA regions and more than 1,000,000 DNA Sites in your blood to detect signals indicative of cancer

Screens

Screens for circulating tumor DNA (ctDNA) in blood for cancer

Analyze

Analyzes mutation patterns in ctDNA

Detects

Detects over 110 different types of cancer from a single blood sample

Identifies

Identifies the potential source of cancer signal by suggesting their likely origin of where the cancer is in the body; enabling targeted treatment

What is Multi-Cancer

Early Detection (MCED) Test?

The Multi-Cancer Early Detection (MCED) test is a simple blood test that detects over 110 different types of cancer that are not usually found with standard screening tests. It is not like the usual cancer tests because this test can pick up a range of cancers that other tests might miss. This test identifies specific cancer-related changes in the DNA that floats freely in our bloodstream. If anything suspicious is found, the test can even suggest where in the body the cancer might be starting.

The test is highly accurate in detecting cancer signals, including cancer at early stages and identifying their likely origin which is particularly useful in planning the next course of action. It helps
bring focus on where the cancer is for treatment, if detected.

THE MULTI-CANCER

EARLY DETECTION (MCED) TEST

Our bodies shed DNA from all cells, including cancer cells, into the bloodstream. As cancer grows, the amount of this DNA in the blood increases. The Multi-Cancer Early Detection (MCED) test looks for specific changes in this DNA that suggest cancer is present. By analyzing these changes, the test can often tell where the cancer is starting to grow.

This test is mainly recommended for people who are at higher risk for cancer, adults, or those with family history of cancer. It complements other regular cancer screening methods to help detect cancer
early to greatly improve treatment success and reduce the costs and complexities of later-stage treatments. Finding cancer early can make a huge difference. It means better chances of beating the cancer, less invasive treatments, and generally lower healthcare costs. With Multi-Cancer Early Detection (MCED) test, you can catch cancer sooner, which can make treatments more effective.

The test can detect various cancers including Lung, Colorectal, Liver, Breast, Uterine, Ovarian, Cervical, Thyroid, Blood, Gastric, Skin, Pancreatic, Prostate, Bladder, Kidney, Head & Neck and Brain cancers.

UNDERSTANDING YOUR TEST RESULTS

Negative Result

No signs of cancer were found, but it’s important to continue with other regular cancer screenings.

Positive Result

The test spotted something that might be cancer. More tests will be needed to confirm if it is really cancer.

Remember, while this test can provide valuable insights, it is just one part of your overall health screening and care plan. Always discuss your options and what the results mean with your healthcare provider.

MORE THAN 110 Type of

Cancers tested

Breast Cancers
  1. Basal (Triple-Negative) Carcinomas
  2. Ductal Carcinomas
  3. ER-Positive & PR-Positive Carcinomas
  4. HER-Positive Carcinomas
  5. Lobular Carcinomas
  6. Luminal Carcinomas
  7. Carcinomas
  8. Metastatic Breast Cancers
  9. Invasive lobular carcinoma
  10. Paget’s disease of the breast
  11. Male breast cancer
  12. Papillary carcinoma
Lung Cancers
  1. Adenocarcinomas
  2. Malignant Pleural Mesotheliomas
  3. Non-Small Cell Lung Cancers
    (NSCLC)
  4. Squamous Cell Carcinomas
  5. Large Cell Carcinomas
  6. Small Cell Lung Cancers (SCLC)
Colorectal Cancers
  1. Adenocarcinomas
Prostate Cancers
  1. Adenocarcinomas
  2. Advanced Prostate Cancers
  3. Ductal Carcinomas
Gastric Cancers
  1. Adenocarcinomas
  2. Adenomas
  3. Gastrointestinal Stromal Tumors (GIST)
Liver Cancers
  1. Cholangiocarcinomas
  2. Hepatoblastomas
  3. Hepatocellular Carcinomas
Cervical Cancers
  1. Squamous cell carcinoma
  2. Cervical adenocarcinomas
Thyroid Cancers
  1. Adenoma-Nodule-Goitre
  2. Anaplastic Carcinomas
  3. Papillary Carcinomas
Head and Neck Cancer
  1. Nasopharyngeal Cancer
  2. Oropharyngeal Cancer
  3. Laryngeal Cancer
  4. Salivary Cancer
  5. Oral Cancer
  6. Esophageal Cancer
Bladder Cancer
  1. Adenocarcinomas
  2. Transitional Cell Carcinomas
  3. Urothelial carcinoma
Pancreatic Cancer
  1. Ductal Adenocarcinomas
  2. Ductal Carcinomas
Kidney Cancer
  1. Clear Cell Renal Cell Carcinoma
  2. Wilms Tumor
Ovarian Cancer
  1. Germ cell tumors
  2. Ovarian stromal tumors
  3. Endometrioid
  4. Epithelial ovarian tumors
  5. Mucinous carcinoma
  6. Clear-cell adenocarcinoma
  7. Serous carcinoma
  8. Carcinosarcoma
Melanomas
  1. Cutaneous Melanomas
  2. Malignant Melanomas
  3. Mucosal Melanomas
  4. Ocular Melanomas
  5. Uveal Melanomas
Leukemia
  1. Acute Lymphoblastic Leukemia (ALL)
  2. Acute Myeloid Leukemia (AML)
  3. Acute Promyelocytic Leukemia (APML; APL)
  4. Atypical Chronic Myeloid Leukemia (aCML)
  5. Chronic Lymphocytic Leukemia (CLL)
  6. Chronic Myeloid Leukemia (CML)
  7. Chronic Myelomonocytic Leukemia (CMML)
  8. Hairy Cell Leukemia
  9. Juvenile Myelomonocytic Leukemia
  10. Chronic Neutrophilic Leukemia
Myeloid Neoplasms
  1. Myelodysplastic Syndromes (MDS)
  2. Myeloproliferative Neoplasms (MPN)
  3. Multiple Myeloma
  4. Plasma Cell Myeloma
  5. Polycythemia Vera
  6. Primary Myelofibrosis
  7. Systemic Mastocytosis
Endometrial Carcinoma
  1. Epithelial Carcinomas
  2. Granulosa Cell Tumors
  3. Mixed Adenosquamous Carcinomas
  4. Mucinous Carcinomas
  5. Serous Carcinomas
Lymphomas
  1. Anaplastic Large Cell Lymphomas
  2. B Cell Lymphomas
  3. Burkitt Lymphomas
  4. Diffuse Large B Cell Lymphomas
  5. Follicular Lymphomas
  6. Hodgkin lymphoma
  7. Lymphocytic Lymphomas
  8. Mantle Cell Lymphomas
  9. Marginal Zone Lymphomas
  10. Mucosa-Associated Lymphoid Tissue
    (MALT) Lymphomas
  11. Non-Hodgkin Lymphomas
  12. Primary Cutaneous Lymphomas
  13. Small Lymphocytic Lymphomas
  14. T Cell Lymphomas
Sarcoma
  1. Askins Tumors
  2. Biphenotypic Sarcomas with Myogenic & Neural Differentiation
  3. Clear Cell Sarcomas
  4. Congenital (Infantile) Fibrosarcomas
  5. Desmoplastic Small Round Cell Tumors
  6. Ewing’s Sarcomas
  7. Fibrosarcomas
  8. Myofibroblastic Sarcomas
  9. Rhabdomyosarcomas
  10. Small Round Cell Tumors
Brain Cancers
  1. Anaplastic Glial Tumors
  2. Astrocytomas
  3.  Ependymomas
  4. Glioblastomas
  5. Gliomas
  6. Medulloblastomas
  7. Meningiomas
  8. Oligodendrogliomas

Multi-Cancer Early Detection (MCED) Test can be purchased at any of our partner's branches (Pathlab nationwide)

FAQs

No, it detects most types but not all cancers. It's used to complement other screening tests.

This test is highly accurate in detecting cancer signals, including cancer at early stages and identifying their likely origin.

A positive result means that signs of cancer were detected. You'll need to undergo addition test to confirm the presence of cancer. 

A negative result means no signs of cancer were found. However, continue with regular screenings as advised by your provider. 

A healthcare provider will draw a blood sample from you, which is then analyzed for signs of cancer

The test involves a simple blood draw, similar to a routine blood test, so any pain in minimal. 

Results are typically returned to your healthcare provider within 14-21 days after the sample is taken.

The test can identify more than 110 types of cancers including Lung, Colorectal, Liver, Breast, Uterine, Ovarian, Cervical, Leukemia, Gastric, Skin, Pancreatic, Prostate, Bladder, Kidney, Brain Thyroid, Head and Neck, Myeloid, Lymphoma, Sarcoma.

The Multi-Cancer early Detection (MCED) test is recommended for use in adults with an elevated risk for cancer and for those who are concerned about their cancer risk. 

It is recommended to take the Multi-Cancer Early Detection (MCED) test at least once a year. However if you belong to a high-risk group with a family history of cancer, consider taking the test every six months to ensure more vigilant monitoring. Always discuss the best screening schedule with your healthcare provider based on your individual risk factors. 

No, it is intended to be used in conjunction with other screening methods, not as a replacement. 

Discuss your results and next steps with our healthcare professional, whether they are positive or negative. 

You may screen for MCED at any Pathlab branches near you. 

Home
Account
Cart